Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease

Vincent Yi Fong Su, Yu Sheng Chang, Yu Wen Hu, Man Hsin Hung, Shuo Ming Ou, Fa Yauh Lee, Kun Ta Chou, Kuang Yao Yang, Diahn Warng Perng, Tzeng Ji Chen, Chia Jen Liu

研究成果: 雜誌貢獻文章同行評審

18 引文 斯高帕斯(Scopus)

摘要

Beta (b)-blockers are under-prescribed in patients with heart failure (HF) and concurrent chronic obstructive pulmonary disease (COPD) due to concerns about adverse pulmonary effects and a poor understanding of the effects of these drugs. We aimed to evaluate the survival effects of b-blockers in patients with coexistent HF and COPD. Using the Taiwan National Health Insurance Research Database, we conducted a nationwide population-based study. Patients with coexistent HF and COPD diagnosed between 2000 and 2009 were enrolled. Doses of the 3 b-blockers proven to be beneficial to HF (carvedilol, bisoprolol, and metoprolol) during the study period were extracted. The primary endpoint was cumulative survival. Patients were followed until December 31, 2009. The study included 11,558 subjects, with a mean follow-up period of 4.07 years. After adjustment for age, sex, comorbidities, and severity of HF and COPD, bisoprolol use showed a dose-response survival benefit [low dose: adjusted hazard ratio (HR)1/40.76, 95% confidence interval (CI)=0.59-0.97, P=0.030; high dose: adjusted HR=0.40, 95% CI=0.26-0.63, P
原文英語
文章編號e2427
期刊Medicine (United States)
95
發行號5
DOIs
出版狀態已發佈 - 2016

ASJC Scopus subject areas

  • 醫藥 (全部)

指紋

深入研究「Carvedilol, bisoprolol, and metoprolol use in patients with coexistent heart failure and chronic obstructive pulmonary disease」主題。共同形成了獨特的指紋。

引用此